Busby J, et al. - Among 44 poorly-controlled severe oral corticosteroid (OCS)-dependent asthmatics, researchers assessed changes in type-2 biomarkers and related cytokines following treatment with prednisolone. Following a 7-day prednisolone boost (0.5 mg/kg), they measured type-2 biomarkers and related cytokines (IL-5, IL-13), lung function and asthma symptoms among the participants for up to 88 days. They found reduced median blood eosinophils, periostin, FeNO, IL-5 and IL-13 in relation to high-dose OCS. In addition, they noted small improvements in mean FEV₁ and (Asthma Control Questionnaire) ACQ-7 score. At 1-month after the intervention, study measures returned to baseline. After rescue OCS, 1 month was sufficient before using type-2 biomarkers to guide long-term therapy.